patient had a complete response and four patients had partial
responses (two unconfirmed).
-- SNS-595 has been generally well tolerated in this trial, with a low
rate of febrile neutropenia or other Grade 3/4 adverse events and
manageable Grade 1/2 nausea or vomiting. Based on the drug's
observed safety profile and indications of clinical activity,
Sunesis amended the protocol to explore a higher dose of SNS-595 in
this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-
eight days, and Sunesis anticipates enrolling approximately 30
patients at this dose in the third quarter of this year.
-- Data from this trial has been accepted for presentation at the 44th
ASCO Annual Meeting.
-- Sunesis updated the results from the company's Phase 1 clinical trial
of single-agent SNS-595 in patients with relapsed or refractory acute
leukemias, which had previously been reported at the 49th Annual
Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia
in December 2007. Since the ASH presentation, an additional patient in
this trial has achieved a complete remission.
-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of
50 mg/m2 or greater on a weekly dose schedule have now achieved bone
marrow blast reductions to less than five percent, and five of these
12 patients achieved either complete remission, complete remission
without platelet recovery or complete remission with incomplete
recovery of normal hematopoietic blood elements.
-- SNS-595 was generally well tolerated in this trial, with a
dose-limiting toxicity of reversible Grade 3/4 oral mucositis.
-- Based on these promising results, Sunesis
|SOURCE Sunesis Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved